Patents by Inventor Lynn Dickey

Lynn Dickey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240084541
    Abstract: A connection device for fastening two expanded cellular confinement structures includes: an insertion member; an integral shank extending perpendicular from the insertion member; and an integral handle member extending perpendicular from the shank at an end of the shank remote from the insertion member. One or more barbs may project from the insertion member. The device can have a washer section between the handle member and insertion member. The handle can be curved, or it can be in the shape of a polygon.
    Type: Application
    Filed: November 17, 2023
    Publication date: March 14, 2024
    Inventors: Michael James Dickey, Bryan Scott Wedin, Cory Scott Schneider, Katie Lynn Bouchard, Joseph Paul George, Jennifer Ann Vander Linden
  • Publication number: 20140205619
    Abstract: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza. The hemagglutinin may be expressed in plants including duckweed. The invention also encompasses recombinant vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals against influenza. It encompasses also a vaccination regimen compatible with the DIVA strategy, including a prime-boost scheme using vector and subunit vaccines.
    Type: Application
    Filed: January 13, 2014
    Publication date: July 24, 2014
    Applicants: BIOLEX THERAPEUTICS, INC., MERIAL LIMITED
    Inventors: Xuan Guo, Michel Bublot, Joyce Anita Pritchard, Lynn Dickey
  • Publication number: 20140205993
    Abstract: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza. The hemagglutinin may be expressed in plants including duckweed. The invention also encompasses recombinant vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals against influenza. It encompasses also a vaccination regimen compatible with the DIVA strategy, including a prime-boost scheme using vector and subunit vaccines.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 24, 2014
    Applicants: Biolex Therapeutics, Inc., Merial Limited
    Inventors: Xuan Guo, Michel Bublot, Joyce Anita Pritchard, Lynn Dickey
  • Publication number: 20120258491
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Application
    Filed: September 14, 2011
    Publication date: October 11, 2012
    Applicant: Biolex Therapeutics, Inc.
    Inventors: Anne-Marie STOMP, Lynn Dickey, John Gasdaska
  • Patent number: 8182803
    Abstract: The present invention provides biologically active variants of human ?-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human ?-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human ?-2b-interferon. The invention encompasses these biologically active variant ?-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant ?-interferon polypeptides and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: May 22, 2012
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Publication number: 20110250177
    Abstract: The present invention provides biologically active variants of human ?-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human ?-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human ?-2b-interferon. The invention encompasses these biologically active variant ?-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant ?-interferon polypeptides and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 11, 2011
    Publication date: October 13, 2011
    Applicant: Biolex Therapeutics, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Patent number: 8022270
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: September 20, 2011
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Patent number: 7959910
    Abstract: The present invention provides biologically active variants of human ?-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human ?-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human ?-2b-interferon. The invention encompasses these biologically active variant ?-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant ?-interferon polypeptides and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: June 14, 2011
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Patent number: 7709699
    Abstract: Methods for high-throughput screening in duckweed are disclosed. In one aspect, these methods are used to identify nucleotide sequences encoding polypeptides of interest. In another aspect, these methods are used to identify nucleotide sequences that modulate the expression of a target nucleotide sequence. The methods combine the predictive benefits of screening in whole plants with the speed and efficiency of a high throughput system.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: May 4, 2010
    Assignee: Biolex Therapeutics, Inc.
    Inventors: Anne-Marie Stomp, Lynn Dickey, Billy Houghteling, Nirmala Rajbhandari
  • Publication number: 20090282584
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Application
    Filed: July 16, 2007
    Publication date: November 12, 2009
    Applicant: BIOLEX, INC.
    Inventors: ANNE-MARIE STOMP, LYNN DICKEY, JOHN GASDASKA
  • Publication number: 20080066200
    Abstract: Methods for altering the N-glycosylation pattern of proteins in higher plants are provided. The methods comprise introducing into the plant a recombinant construct that provides for the inhibition of expression of ?1,3-fucosyltransferase (FucT) and ?1,2-xylosyltransferase (XylT) in a plant. Use of these constructs to inhibit or suppress expression of both of these enzymes, and isoforms thereof, advantageously provides for the production of endogenous and heterologous proteins having a “humanized” N-glycosylation pattern without impacting plant growth and development. Stably transformed higher plants having this protein N-glycosylation pattern are provided. Glycoprotein compositions, including monoclonal antibody compositions, having substantially homogeneous glycosylation profiles, and which are substantially homogeneous for the G0 glycoform, are also provided.
    Type: Application
    Filed: January 17, 2007
    Publication date: March 13, 2008
    Applicant: Biolex, Inc.
    Inventors: Lynn Dickey, Kevin Cox, Charles Peele
  • Publication number: 20080060092
    Abstract: Methods for altering the N-glycosylation pattern of proteins in higher plants are provided. The methods comprise introducing into the plant a recombinant construct that provides for the inhibition of expression of ?1,3-fucosyltransferase (FucT) and ?1,2-xylosyltransferase (XylT) in a plant. Use of these constructs to inhibit or suppress expression of both of these enzymes, and isoforms thereof, advantageously provides for the production of endogenous and heterologous proteins having a “humanized” N-glycosylation pattern without impacting plant growth and development. Stably transformed higher plants having this protein N-glycosylation pattern are provided. Glycoprotein compositions, including monoclonal antibody compositions, having substantially homogeneous glycosylation profiles, and which are substantially homogeneous for the G0 glycoform, are also provided.
    Type: Application
    Filed: January 17, 2007
    Publication date: March 6, 2008
    Applicant: Biolex, Inc.
    Inventors: Lynn Dickey, Kevin Cox, Charles Peele, Ming-Bo Wang
  • Publication number: 20070180583
    Abstract: Compositions and methods for regulating expression of nucleotide sequences of interest in a plant are provided. Compositions include novel nucleic acid molecules, and variants and fragments thereof, for expression control elements isolated from the Lemnaceae ubiquitin, r-histone and chitinase genes. A method for expressing a nucleotide sequence of interest in a plant using the expression control elements disclosed herein is further provided. The method includes introducing into a plant or plant cell or nodule an expression construct comprising an expression control element of the present invention operably linked to a nucleotide sequence of interest. In particular, the compositions and methods find use in enhancing expression of nucleotide sequences of interest in duckweed. Also provided is a novel Lemnaceae signal peptide-encoding sequence and the signal peptide encoded thereby.
    Type: Application
    Filed: January 16, 2007
    Publication date: August 2, 2007
    Applicant: Biolex, Inc.
    Inventors: Lynn Dickey, Kevin Cox, Charles Peele
  • Publication number: 20070128162
    Abstract: The present invention provides biologically active variants of human ?-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human ?-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human ?-2b-interferon. The invention encompasses these biologically active variant ?-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant ?-interferon polypeptides and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 16, 2004
    Publication date: June 7, 2007
    Applicant: Biolex, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Publication number: 20060195946
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Application
    Filed: September 30, 2003
    Publication date: August 31, 2006
    Applicant: Biolex, Inc.
    Inventors: Lynn Dickey, John Gasdaska, Kevin Cox
  • Publication number: 20050262592
    Abstract: The present invention provides methods and compositions for the production of recombinant plasminogen, microplasminogen, and fragments thereof in a duckweed expression system. It is the novel finding of the present invention that a duckweed expression system may be used to produce high levels of plasminogen and microplasminogen. The duckweed-produced plasminogen and microplasminogen can be activated to produce a polypeptide having protease activity. Thus, the invention encompasses methods for the expression of plasminogen, microplasminogen, and fragments thereof in duckweed, duckweed plants that are transformed with expression cassettes for the expression of plasminogen, microplasminogen, and fragments thereof, and nucleic acids comprising nucleotide sequences encoding plasminogen, microplasminogen, and fragments thereof, where these nucleotide sequences are modified to enhance their expression in duckweed.
    Type: Application
    Filed: February 11, 2005
    Publication date: November 24, 2005
    Applicant: Biolex, Inc.
    Inventors: David Spencer, Lynn Dickey, John Gasdaska, Xiaowei Wang, Kevin Cox, Charles Peele
  • Publication number: 20050060776
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Application
    Filed: June 22, 2004
    Publication date: March 17, 2005
    Applicant: Biolex, Inc.
    Inventors: Anne-Marie Stomp, Lynn Dickey, John Gasdaska
  • Patent number: 6815184
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: November 9, 2004
    Assignee: Biolex, Inc.
    Inventors: Anne-Marie Stomp, Lynn Dickey, John Gasdaska
  • Publication number: 20030033630
    Abstract: Methods for high-throughput screening in duckweed are disclosed. In one aspect, these methods are used to identify nucleotide sequences encoding polypeptides of interest. In another aspect, these methods are used to identify nucleotide sequences that modulate the expression of a target nucleotide sequence. The methods combine the predictive benefits of screening in whole plants with the speed and efficiency of a high throughput system.
    Type: Application
    Filed: May 30, 2002
    Publication date: February 13, 2003
    Applicant: Biolex, Inc.
    Inventors: Anne-Marie Stomp, Lynn Dickey, Billy Houghteling, Nirmala Rajbhandari
  • Publication number: 20020088027
    Abstract: Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.
    Type: Application
    Filed: July 26, 2001
    Publication date: July 4, 2002
    Inventors: Anne-Marie Stomp, Lynn Dickey, John Gasdaska